ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1806

Performance of the Brief Index of Lupus Damage (BILD) in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort

Patricia P. Katz1, Maria Dall'Era2, Laura Trupin3, Stephanie Rush4, Charles G. Helmick5, Lindsey A. Criswell4 and Jinoos Yazdany3, 1Medicine, University of California, San Francisco, San Francisco, CA, 2Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 4University of California, San Francisco, San Francisco, CA, 5Centers for Disease Control and Prevention, Atlanta, GA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity, patient-reported outcome measures and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Patient Outcomes, Preferences, and Attitudes I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The BILD1,2 was developed and validated as a measure of SLE organ damage for use in epidemiologic studies in which administration of the SLICC Damage Index (SDI) by physicians is not feasible. This analysis examines the criterion validity and other performance characteristics of the BILD in 4 racial/ethnic groups.

Methods: Data were from the California Lupus Epidemiology Study (CLUES), a population-based, multi-ethnic SLE cohort. Subjects participated in a research clinic visit during which the SDI was completed by a physician and completed a structured interview administered by a trained interviewer in which BILD was administered. Race and ethnicity were self-reported. Prevalence-adjusted bias-adjusted kappa (PABAK) coefficients were calculated to determine item-by-item agreement between physicians and subjects. Spearman correlation coefficients examined relationships between BILD and SDI scores. Construct validity was evaluated by examining relationship of sociodemographic, disease-specific, general health, and health care utilization factors with BILD scores. BILD scores are not normally distributed, so were divided into rough quartiles for these analyses and differences tested using analysis of variance or chi-square analysis. All analyses were performed separately for each of 4 racial/ethnic groups: white (W), Hispanic (H), African American (AA), and Asian (AS).

Results: The sample (n=281) was 29% W, 23% H, 11% AA, and 37% AS; 89% female; mean age 45 (±14) years; 22% with education ≤high school; 12% with poverty-level income; mean disease duration 16 (±10) years. 85% of interviews were completed in English. Correlations with SDI ranged from 0.45 for AA subjects to 0.80 for AS subjects (Table). All PABAK coefficients were >0.75, with the exception of 1 item for H subjects. For each racial/ethnic group, individuals with higher BILD scores had disease of longer duration; were less likely to be working; had poorer self-rated health, physical functioning and pain interference; reported more physician visits during the previous year; and were more likely to have been hospitalized in the previous year. No differences were seen by education or health literacy. Among H and AS groups, no differences were seen in BILD performance by language of administration.

Conclusion: The BILD functioned reasonably well in all 4 racial/ethnic groups, regardless of language of administration. Correspondence with physician-completed SDI was moderate to good; correlations were lower for AA and H patients where sample size was smaller. Future research will examine the source of discrepancies (patient or physician reports). Results provide further support the use of the BILD in observational and epidemiologic research, including among racial/ethnic minorities.

1Yazdany, et al., Arthritis Care Res 2011; 63:1170

2Katz, et al., Arthritis Care Res 2014; 66:1057

Table. Descriptive information of BILD and SLICC Damage Index score overall and by racial/ethnic group

n

Scores > 0

Mean

Median

IQR

Maximum

Correlation with SDI

All

281

BILD

199 (71%)

1.8

1

0 — 3

12

0.65

SLICC DI

144 (51%)

1.2

1

0 — 2

7

White (W)

82

BILD

56 (68%)

1.8

1

0 — 3

9

0.73

SLICC DI

35 (44%)

1.1

0

0 — 2

6

Hispanic (H)

65

BILD

47 (72%)

2.1

1

0 — 4

12

0.57

SLICC DI

30 (46%)

1.2

0

0 — 2

6

African-American (AA)

31

BILD

26 (84%)

2.1

1

0 — 3

9

0.45

SLICC DI

22 ( 71%)

1.6

1

0 — 2

6

Asian (AS)

103

BILD

70 (68%)

1.5

1

0 — 2

7

0.80

SLICC DI

52 (51%)

1.0

1

0 — 1

6


Disclosure: P. P. Katz, Bristol-Myers Squibb, 2; M. Dall'Era, None; L. Trupin, None; S. Rush, None; C. G. Helmick, None; L. A. Criswell, None; J. Yazdany, None.

To cite this abstract in AMA style:

Katz PP, Dall'Era M, Trupin L, Rush S, Helmick CG, Criswell LA, Yazdany J. Performance of the Brief Index of Lupus Damage (BILD) in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/performance-of-the-brief-index-of-lupus-damage-bild-in-a-multi-ethnic-population-based-systemic-lupus-erythematosus-sle-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-the-brief-index-of-lupus-damage-bild-in-a-multi-ethnic-population-based-systemic-lupus-erythematosus-sle-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology